Cirrhotic refractory ascites: Pathogenesis, current therapeutic strategies, and future directions
Hepatobiliary Communications · 2026
DOI: 10.1016/j.hbc.2026.100004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatobiliary Communications, 2026. Verfasst von Linxin Zhou und 1 weiteren Autor:innen. Die Arbeit nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Refractory ascites (RA) develops in approximately 10% of patients with cirrhotic ascites. The onset of RA heralds entry into a high-mortality-risk phase, characterized by a marked decline in 1-year survival rates, recurrent hospitalizations, worsening renal function, hyponatremia, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and significantly impaired quality of life.In recent years, driven by advances in the pathophysiological understanding of portal hypertension and updated clinical trial data, the management strategy for RA has evolved from a passive approach of “repeated large-volume paracentesis plus albumin supplementation” to a comprehensive model encompassing “stratified assessment, early warning for complications, combined device and interventional therapies, and earlier transplantation.” The pathophysiology of RA is multifactorial, involving a complex interplay of portal hypertension, splanchnic vasodilation, reduced effective arterial blood volume, neurohumoral overactivation, renal sodium and water retention, systemic inflammation and immune dysregulation, and disordered cardiorenal coupling, all of which perpetuate a vicious cycle. The management of RA follows a stepwise algorithm. Large-volume paracentesis with albumin infusion serves as the cornerstone palliative therapy. In appropriately selected patients, Transjugular Intrahepatic Portosystemic Shunt (TIPS) can effectively reduce portal pressure and improve both ascites control and survival. Liver transplantation remains the only definitive, curative treatment that can reverse disease progression. Other emerging modalities, including the automated low-flow ascites pump (Alfapump®) and cell-free concentrated ascites reinfusion therapy (CART), may serve as alternative or bridging strategies for specific patient populations; however, their routine clinical adoption is limited by variable efficacy, safety profiles, and a lack of high-quality evidence. Optimal management of RA-related complications—spontaneous bacterial peritonitis, acute kidney injury, malnutrition, and the nuanced use of non-selective beta-blockers—requires individualized approaches. Future directions emphasize precision patient stratification, optimization of intervention timing, and the development of novel therapies targeting key pathophysiological pathways, marking a paradigm shift from sequential algorithms toward personalized precision medicine.
Zitieren
APA
Zhou, L., & Lin, J. (2026). Cirrhotic refractory ascites: Pathogenesis, current therapeutic strategies, and future directions. Hepatobiliary Communications. https://doi.org/10.1016/j.hbc.2026.100004
Vancouver
Zhou L, Lin J. Cirrhotic refractory ascites: Pathogenesis, current therapeutic strategies, and future directions. Hepatobiliary Communications. 2026. doi:10.1016/j.hbc.2026.100004
BibTeX
@article{Zhou2026,
author = {Zhou, Linxin and Lin, Jianhui},
title = {Cirrhotic refractory ascites: Pathogenesis, current therapeutic strategies, and future directions},
journal = {Hepatobiliary Communications},
year = {2026},
doi = {10.1016/j.hbc.2026.100004}
}
EUVIMED